Literature DB >> 33708550

Thyroid lobectomy in patients with differentiated thyroid cancer: an analysis of the clinical outcomes in a nationwide multicenter study.

Juan J Díez1,2, Victoria Alcázar3, Pedro Iglesias1,2, Ana Romero-Lluch4, Julia Sastre5, Begoña Pérez Corral6, Carles Zafón7, Juan Carlos Galofré8, María José Pamplona9.   

Abstract

BACKGROUND: Total thyroidectomy is the standard initial surgery for differentiated thyroid carcinoma (DTC), but the extent of the thyroidectomy remains controversial. Thyroid lobectomy (TL) has been widely used in eastern countries; however, its use has not been generalized in western countries, including Spain. Our aims were to analyse the clinical outcome of a multicentre nation-wide cohort of DTC patients treated by TL and to assess the proportion of patients who required completion of the thyroidectomy and who presented disease recurrence.
METHODS: We retrospectively analyzed patients who underwent TL for DTC and were followed-up for ≥12 months. We collected demographic, clinical, and histopathological data. Dynamic risk stratification (DRS) was performed at 12 months and at last visit.
RESULTS: One hundred and sixty-four patients (128 women, mean age 50.8 years, median follow-up 45.4 months) from 9 hospitals were included. There were 158 cases of papillary and 6 of follicular thyroid carcinoma (FTC). Remission of the disease (excellent response) was shown in 71.6% of the patients at 12 months and in 74.4% at the end of follow-up. At that time, there were 34 patients (20.7%) with indeterminate response, 6 (3.7%) with biochemical incomplete response, and 2 (1.2%) with structural incomplete response. Completion of the thyroidectomy was necessary in 8 patients (4.9%), but only 3 of them (1.8%) had disease recurrence.
CONCLUSIONS: These results, obtained in real clinical practice, suggest that TL is a safe operative option for selected patients with DTC and that the intensity of the treatment must be tailored according to the presurgical tumor-associated risk, in line with a personalized medicine. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Differentiated thyroid carcinoma (DTC); dynamic risk stratification (DRS); lobectomy; thyroid surgery; tumor recurrence

Year:  2021        PMID: 33708550      PMCID: PMC7944057          DOI: 10.21037/gs-20-712

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  35 in total

1.  A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study.

Authors:  Hyemi Kwon; Min Ji Jeon; Won Gu Kim; Suyeon Park; Mijin Kim; Dong Eun Song; Tae-Yon Sung; Jong Ho Yoon; Suck Joon Hong; Tae Yong Kim; Young Kee Shong; Won Bae Kim
Journal:  Eur J Endocrinol       Date:  2017-01-15       Impact factor: 6.664

Review 2.  Role of hemithyroidectomy in differentiated thyroid cancer.

Authors:  Bianca Gibelli; Rosa Dionisio; Mohssen Ansarin
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2015-04       Impact factor: 2.064

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1-4 cm: Preliminary results.

Authors:  Min Joo Kim; Myung-Chul Lee; Guk Haeng Lee; Hoon Sung Choi; Sun Wook Cho; Su-Jin Kim; Kyu Eun Lee; Young Joo Park; Do Joon Park
Journal:  Clin Endocrinol (Oxf)       Date:  2017-04-18       Impact factor: 3.478

Review 5.  Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.

Authors:  Carles Zafon; Juan J Díez; Juan C Galofré; David S Cooper
Journal:  Eur Thyroid J       Date:  2017-03-03

Review 6.  Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: A meta-analysis.

Authors:  Francisco Igor B Macedo; Vijay K Mittal
Journal:  Surg Oncol       Date:  2015-04-22       Impact factor: 3.279

7.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

Review 8.  Update on differentiated thyroid cancer staging.

Authors:  Denise P Momesso; R Michael Tuttle
Journal:  Endocrinol Metab Clin North Am       Date:  2014-06       Impact factor: 4.741

9.  Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.

Authors:  Kenichi Matsuzu; Kiminori Sugino; Katsuhiko Masudo; Mitsuji Nagahama; Wataru Kitagawa; Hiroshi Shibuya; Keiko Ohkuwa; Takashi Uruno; Akifumi Suzuki; Syunsuke Magoshi; Junko Akaishi; Chie Masaki; Michikazu Kawano; Nobuyasu Suganuma; Yasushi Rino; Munetaka Masuda; Kaori Kameyama; Hiroshi Takami; Koichi Ito
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

Review 10.  How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.

Authors:  Carole Spencer; Jonathan LoPresti; Shireen Fatemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

View more
  1 in total

Review 1.  Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer.

Authors:  Ilaria Stramazzo; Silvia Capriello; Alessandro Antonelli; Poupak Fallahi; Marco Centanni; Camilla Virili
Journal:  Hormones (Athens)       Date:  2022-06-02       Impact factor: 2.885

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.